Ross Givens
Chief Market Strategist
Ross Givens is a veteran trader with over 15 years of experience and a former VP at a major Wall Street investment bank. Specializing in small-cap stocks and momentum-driven plays, Ross identifies high-probability setups before they hit the mainstream. As Lead Strategist at Traders Agency, he has guided hundreds of successful trades and developed multiple flagship publications.
The Market Just Changed the Rules
Everyone kept staring at AI. Meanwhile, the part of the market nobody was talking about started doing something we haven’t seen in years.
The Biggest Wealth Transfer of the Decade Starts NOW
The great wealth transfer is happening now in AI stocks. See the 150-year pattern showing who profits when builders go bust and users win.
Bad Timing for Retail Traders
Retail traders just made their biggest tech exit in years. The market’s next move made the timing look even worse – and raises a question about who saw it coming.
I Turned Wall Street's Biggest Mistake Into $15,000.. THIS Is Next
A hedge fund margin call tanked Wall Street stocks—here's how forced selling created a fast $15,000 profit and where capital rotates next.
Forced Sellers Out – Opportunity In
A brutal four-day crash just tore through Wall Street’s hottest trades. But the real setup may only be starting now.
Wall Street Eats Its Own
A brilliant AI investor got trapped. One of Wall Street’s sharpest operators was waiting – and retail traders may be walking into the same setup.
Wall Street's Hottest AI Hedge Fund Just Collapsed... I Bought $100,000
A wall street hedge fund collapse erased a 439% AI winner in days. See how 4:1 leverage and margin calls sparked the tech selloff—and the setup now.
Insane Volatility Under the Surface
Some of the market’s strongest stocks are suddenly getting crushed. The reason may have less to do with the companies than it appears.
SpaceX Stock Is About to Crash... Here's the Exact Day I'm Buying
Is SpaceX stock going to crash? A 911M-share unlock on Aug 6 could trigger a 50% drop into the $50s -- here's the exact buy price.
The Market’s Strange Split
Investors are bracing for a broader decline. But beneath the surface, the market is sending a very different signal.
The FDA Just Changed Robotics Forever... Everyone Bought the Wrong Stock
FDA's new De Novo ruling ends one company's grip on surgical robots. Here's the medical robotics investing angle everyone's missing—and it's not J&J.
A Massive “Buying Window” Just Opened
Earnings season is bringing one major buyer back into the market. At the same time, one insider signal is becoming unusually scarce.
Stop watching.
Start winning.
50,000+ traders get our daily brief before the market opens.
You're subscribed!
Check your inbox.
Free. No spam. Unsubscribe anytime.
